Une étude de phase I/II, en ouvert, multicentrique visant à déterminer la sécurité d’emploi et l’efficacité du BLZ945 en monothérapie ou en association au PDR001 chez des patients adultes atteints de tumeurs solides avancées

Drug: BLZ945;Drug: PDR001

Inclusion Criteria:

1. Phase I: Patients with advanced/metastatic solid tumors, with measurable or
unmeasurable disease as determined by Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1

2. Phase I: Patients with a site of disease amenable to biopsy, and willing to undergo a
new tumor biopsy at screening, and during treatment.

3. Phase II: Patients with advanced/metastatic/recurrent isocitrate dehydrogenase (IDH)
wild-type glioblastoma, with at least one measurable lesion as determined by RANO

Other protocol defined inclusion criteria may apply

Exclusion Criteria:

1. History of severe hypersensitivity reactions to monoclonal antibodies.

2. Impaired cardiac function or clinically significant cardiac disease.

3. Active autoimmune disease or a documented history of autoimmune disease.

4. Systemic steroid therapy or any immunosuppressive therapy

5. Use of any vaccines against infectious diseases within 4 weeks of initiation of study
treatment.

6. Patient receiving treatment with medications that either strong inducers or inhibitors
of CYP2C8 or CYP3A4/5, or patients receiving medication that prohibits proton pump
inhibitors and that cannot be discontinued at least 1 week prior to start of treatment
and for the duration of the study.

Other protocol defined exclusion criteria may apply.